Ahmad Tarhini, Zeynep Eroglu, Jonathan S. Zager, Ricardo Jorge Gonzalez, Joseph Markowitz, Nikhil I. Khushalani, Lilit Karapetyan, Andrew Scott Brohl, Rogerio Izar Neves, Amod Sarnaik, Matthew Christopher Perez, Pei-Ling Chen, Timothy McCardle, Kenneth Yee Tsai, Lina M. Moreno, Jannisa M. Bautista, Tingyi Li, Xuefeng Wang, Jane Messina, Vernon K. Sondak. "A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.9501